Evidence map›Paper›PMID 42633358›Full record

ReviewADMET & DMPK2026

Structure-activity relationship of captopril derivatives as New Delhi metallo beta-lactamase 1 inhibitors.

Ikhlas Jarrar

Abstract readReview
In one paragraph

Review in ADMET & DMPK, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ikhlas JarrarDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Arab American University, Jenin, Palestine.ORCID https://orcid.org/0000-0002-2232-5928

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: New Delhi Metallo beta-lactamase-1 (NDM-1) is a zinc-dependent enzyme that confers resistance to several antibiotics; therefore, there is an urgent requirement for effective inhibitors. Captopril has been exploited as a scaffold in the design of NDM-1 inhibitors; however, a comparative evaluation of these derivatives from structure activity relationship perspective has not been conducted. This review aimed to evaluate captopril-derived NDM-1 inhibitors and to identify possible structure-activity relationships that govern their NDM-1 inhibitory action. Experimental approach: The literature was searched in a structured manner using scholarly databases to locate original studies that reported captopril derivatives and evaluated them in vitro against NDM-1 with the explicit reporting of the inhibitory concentration values (IC Important findings: The activity of captopril derivatives depends on the free thiol group (masking it reduces activity), with stereochemistry governing optimal binding orientation within the NDM-1 active site, hydrophobic substitutions enhance activity only within steric limits, and the carboxylate motif serves as a secondary anchoring feature. Conclusion: Captopril emerges as a promising scaffold for NDM-1 inhibitors and reveals significant structural features associated with NDM-1 inhibitors. Despite limited in vivo data and heterogeneity in assay conditions, the findings provide a rational framework for optimizing captopril-inspired NDM-1 inhibitors.

Indexed as

assay heterogenicityfluorinated analoguesmercaptopropionamidepyrrolidine ringstereochemical effectsZinc binding group

Identifiers

PMID42633358
PMCPMC13499674

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.